Drug Approval | July 04, 2023
Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Supply readiness follows months of manufacturing to ensure timely and ample supply
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Subscribe To Our Newsletter & Stay Updated
